Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 8 months ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
Potential Reversibility of ATTR-CM through Anti-ATTR Amyloid Antibodies
Author(s): Marianna Fontana Added: 2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients. Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin… View more

Heart Failure
Emerging Toxicities, Translational Research and Reverse Cardio-oncology
Author(s): Massimiliano Camilli , Luca Maggio , Lorenzo Tinti , et al Added: 8 months ago

CV Disease in Special Populations

Heart Failure
Development of Small-molecule SERCA Stimulators
Author(s): Antonio Zaza , Marcella Rocchetti Added: 5 months ago

Heart Failure
ECO 24: Semaglutide in Body Weight & Reversion of Normoglycaemia: STEP 10
Author(s): Barbara McGowan Added: 1 year ago
ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk).This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes. The primary… View more

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 2 years ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 6 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Renal Metabolic

Guidelines & Statements
HFSA 25: 96-week Analysis from FOREST-HCM
Author(s): Ahmad Masri Added: 2 months ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34… View more

Heart Failure
TCT 23: 5 Trials That Changed My Practice
Author(s): Mirvat Alasnag Added: 2 years ago
TCT 23 - We are joined by Dr Mirvat Alasnag (The King Fahd Armed Forces Hospital, SA) for an insightful summary of the late-breaking trials that are expected to have an impact on interventional science and clinical practice. Trials covered in detail include: Agent IDE ALIGN-AR PARTNER 3 EVOLUT Low-Risk TRISCEND Recorded remotely from Jeddah, 2023. Editor: Jordan Rance Video Specialist:… View more

Intervention